Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRK6 | P43250 | 2/20 | 0.49 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.44 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.44 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.42 |
| ▸ | TGFBR1 | P36897 | 3/20 | 0.40 |
| ▸ | TNIK | Q9UKE5 | 3/20 | 0.40 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.40 |
| ▸ | AMY1A | P0DUB6 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | CTSA | P10619 | 1/20 | 0.38 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | STIM1 | Q13586 | 2/20 | 0.37 |
| ▸ | ORAI1 | Q96D31 | 2/20 | 0.37 |
| ▸ | GRM5 | P41594 | 1/20 | 0.37 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6450102 | 0.86 | GAA (0.50) | GRK6NR1H2NR1H3NPC1RAB9A | |
| SCHEMBL6449669 | 0.84 | MGAM (0.49) | GRK6NR1H2NR1H3ADORA2AADORA1 | |
| SCHEMBL6449668 | 0.83 | SMN1; SMN2 (0.55) | GRK6NR1H2NR1H3NPC1RAB9A | |
| SCHEMBL6452524 | 0.81 | DCUN1D1 (0.50) | GRK6NR1H2NR1H3ADORA2ATGFBR1 | |
| SCHEMBL6451523 | 0.80 | NR1H2 (0.65) | GRK6NR1H2NR1H3ADORA2AADORA1 | |
| SCHEMBL6448919 | 0.77 | GRK6 (0.47) | GRK6NR1H2NR1H3ADORA2ATNIK | |
| SCHEMBL6449633 | 0.75 | CCR1 (0.44) | NR1H2NR1H3TGFBR1NPC1RAB9A | |
| SCHEMBL6452037 | 0.75 | GRK6 (0.46) | GRK6NR1H2NR1H3NPC1RAB9A | |
| SCHEMBL13377809 | 0.74 | CCR1 (0.54) | NR1H2NR1H3TGFBR1NPC1RAB9A | |
| SCHEMBL6448827 | 0.74 | GRK6 (0.47) | GRK6NR1H2NR1H3ADORA2AADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050075375-A1 | Heterocyclic compounds for treating hepatitis C virus | ANADYS PHARMACEUTICALS, INC. (US) | 2005-04-07 | — | — | US | disclosed |
| WO-2004110351-A2 | HETEROCYCLIC COMPOUNDS FOR TREATING HEPATITIS C VIRUS | ANADYS PHARMACEUTICALS, INC. (US) | 2004-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050075375-A1 | Heterocyclic compounds for treating hepatitis C virus | HAVCR2, HCCS, LIPC | GRK6 2654/4885NR1H2 34/4885NR1H3 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.